Johnson & Johnson trials show single-shot COVID-19 vaccine effective

Johnson & Johnson logo
(Image credit: MARK RALSTON/AFP via Getty Images)

Johnson & Johnson's coronavirus vaccine proved safe and provoked an immune response in young and elderly volunteers alike, according to trial results published Wednesday in the New England Journal of Medicine. Most trial participants got just one shot of a high or low vaccine dose, or a placebo, although some people aged 18 to 55 got two doses. Most of the volunteers who got the vaccine produced the neutralizing antibodies, which defend cells from the virus, after 28 days. Researchers reported some side effects, including fever, fatigue, headache, and pain at the injection site. Dr. Paul Stoffels, chief scientific officer at J&J, said the data gave the company "confidence" the vaccine will prove highly effective. Results from the larger phase-three trial are expected later this month.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Harold Maass, The Week US

Harold Maass is a contributing editor at The Week. He has been writing for The Week since the 2001 debut of the U.S. print edition and served as editor of TheWeek.com when it launched in 2008. Harold started his career as a newspaper reporter in South Florida and Haiti. He has previously worked for a variety of news outlets, including The Miami Herald, ABC News and Fox News, and for several years wrote a daily roundup of financial news for The Week and Yahoo Finance.